864932-46-7

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-phenyl-2-(piperazin-1-yl)acetate is used as a precursor in the synthesis of various drugs, particularly those that affect the central nervous system. Its unique structure and properties make it a valuable component in the development of medications targeting mood disorders and depression.
Used in Mental Health Medications:
Methyl 2-phenyl-2-(piperazin-1-yl)acetate is used as an active pharmaceutical ingredient for the treatment of mood disorders and depression. Its sedative and anxiolytic properties contribute to its potential as a therapeutic agent in managing mental health conditions.
Used in Drug Development Research:
Methyl 2-phenyl-2-(piperazin-1-yl)acetate is used as a research compound in the development of new medications for mental health disorders. Its potential applications in this field are being explored through ongoing scientific studies and clinical trials.

Upstream product

• 110-85-0 piperazine 
• 57486-69-8 methyl 2-(2-bromophenyl)acetate 
• 6591-61-3 (S)-Phenylglycine methyl ester 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 347186-48-5 tert-butyl 4-(2-methoxy-2-oxo-1-phenylethyl)piperazine-1-carboxylate 
• 37167-62-7 bromo-phenyl-acetic acid methyl ester 

Downstream Products

• 935854-69-6 [4-(2-Chloro-4-nitro-phenyl)-piperazin-1-yl]-phenyl-acetic acid methyl ester 

Relevant academic research and scientific papers

Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors

NaV1.7 is a particularly compelling target for the treatment of pain. Herein, we report the discovery and evaluation of a series of piperazine amides that exhibit state-dependent inhibition of NaV1.7. After demonstrating significant pharmacodynamic activity with early lead compound 14 in a NaV1.7-dependent behavioural mouse model, we systematically established SAR trends throughout each sector of the scaffold. The information gleaned from this modular analysis was then applied additively to quickly access analogues that encompass an optimal balance of properties, including NaV1.7 potency, selectivity over NaV1.5, aqueous solubility, and microsomal stability.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel

A series of triarylethanolamine inhibitors of the Kv1.5 potassium channel have been prepared and evaluated for their effects in vitro and in vivo. The structure-activity relationship (SAR) studies described herein led to the development of potent, selecti

SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep/wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

ADRENERGIC RECEPTOR ANTAGONISTS

The present invention relates to α1a and/or α1b adrenergic receptor antagonists, which can be used to treat a disease or disorder mediated through α1a and/or α1b adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.

MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES

The present invention is concerned with novel aryl piperidine or piperazine compounds substituted with certain 5-membered heterocycles having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes (Formula (I)). The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes.